<DOC>
	<DOCNO>NCT02852005</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , immunogenicity AIDSVAX B/E vaccine MVA/HIV62B vaccine healthy , HIV-1-uninfected adult previously receive MVA/HIV62B DNA/MVA MVA/MVA vaccine regimens HVTN 205 study .</brief_summary>
	<brief_title>Evaluating Immunogenicity AIDSVAX B/E Vaccine MVA/HIV62B Vaccine Healthy , HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B DNA/MVA MVA/MVA Regimens HVTN 205</brief_title>
	<detailed_description>This study evaluate safety , tolerability , immunogenicity AIDSVAX B/E vaccine MVA/HIV62B vaccine healthy , HIV-1-uninfected adult previously receive MVA/HIV62B DNA/MVA MVA/MVA vaccine regimens part HVTN 205 study . Participants study assign one five group base previous vaccine regimen receive HVTN 205 . Depending group , participant receive MVA/HIV62B vaccine , AIDSVAX B/E vaccine , MVA/HIV62B vaccine AIDSVAX B/E vaccine . All participant receive assign vaccine study entry ( Day 0 ) Month 4 . Participants attend several study visit Month 10 . Visits include physical examination , blood collection , HIV test risk reduction counseling , interview questionnaire . Optional procedure visit include collection rectal fluid , cervical fluid , semen . Study staff contact participants 2 year follow initial study injection follow-up health monitoring .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>General Demographic Criteria : Age 18 55 year Prior participation HVTN 205 assignment treatment ( placebo ) arm : 1 . Assigned HVTN 205 Group 1 Group 3 , receive 4 schedule vaccination ( 2 injection pGA2/JS7 DNA ( month 0 , 2 ) 2 injection MVA/HIV62 ( month 4 , 6 ) ; OR 2 . Assigned HVTN 205 Group 4 , receive least vaccination 1 , 2 4 ( 3 injection MVA/HIV62 month 0 , 2 6 ) . Access participate HVTN clinical research site ( CRS ) willingness follow plan duration study Ability willingness provide inform consent Assessment understanding : volunteer demonstrate understand study ; complete questionnaire prior first vaccination verbal demonstration understand questionnaire item answer incorrectly Willing contact 2 year follow initial study injection . Agrees enroll another study investigational research agent Good general health show medical history , physical exam , screen laboratory test HIVRelated Criteria : Willingness receive HIV test result Willingness discuss HIV infection risk amenable HIV risk reduction counsel . Assessed clinic staff `` low risk '' HIV infection commit maintain behavior consistent low risk HIV exposure last require protocol clinic visit . Laboratory Inclusion Values : Hemogram/Complete Blood Count ( CBC ) Hemoglobin great equal 11.0 g/dL volunteer bear female , great equal 13.0 g/dL volunteer bear male White blood cell count equal 3,300 12,000 cells/mm^3 Total lymphocyte count great equal 800 cells/mm^3 Remaining differential either within institutional normal range site physician approval Platelets equal 125,000 550,000/mm^3 Chemistry Chemistry panel : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase less 1.25 time institutional upper limit normal ; creatinine le equal institutional upper limit normal . Cardiac Troponin T I ( cTnT cTnI ) exceed institutional upper limit normal Virology Negative HIV1 2 blood test : Participants must negative test result HIV infection follow HVTN Lab Program 's instudy HIV test algorithm , prior initial enrollment . Negative hepatitis B surface antigen ( HBsAg ) Negative antihepatitis C virus Ab ( antiHCV ) , negative HCV polymerase chain reaction ( PCR ) antiHCV positive Urine Normal urine : Negative urine glucose , Negative trace urine protein , Negative trace urine hemoglobin ( trace hemoglobin present dipstick , microscopic urinalysis red blood cell level within institutional normal range ) . Reproductive Status Volunteers bear female : negative serum urine beta human chorionic gonadotropin ( Î²HCG ) pregnancy test perform prior vaccination day initial vaccination . Persons NOT reproductive potential due undergone total hysterectomy bilateral oophorectomy ( verified medical record ) , require undergo pregnancy test . Reproductive status : A volunteer bear female must : Agree consistently use effective contraception ( information available protocol ) sexual activity could lead pregnancy least 21 day prior enrollment last require protocol clinic visit . Effective contraception define use follow method : Condoms ( male female ) without spermicide , Diaphragm cervical cap spermicide , Intrauterine device ( IUD ) , Hormonal contraception , Any contraceptive method approve HVTN 114 Protocol Safety Review Team ( PSRT ) Successful vasectomy male partner ( consider successful volunteer report male partner [ 1 ] documentation azoospermia microscopy , [ 2 ] vasectomy 2 year ago resultant pregnancy despite sexual activity postvasectomy ) ; Or reproductive potential , reach menopause ( menses 1 year ) undergone hysterectomy , bilateral oophorectomy , tubal ligation ; Or sexually abstinent . Volunteers born female must also agree seek pregnancy alternative method , artificial insemination vitro fertilization last require protocol clinic visit General Blood product receive within 120 day first vaccination Investigational research agent receive within 30 day first vaccination Body mass index ( BMI ) great equal 40 Volunteer 2 follow cardiac risk factor : Participant report history elevate blood cholesterol define fast LDL great 160 mg/dL ; First degree relative ( eg , mother , father , brother , sister ) coronary artery disease age 50 year ; Current smoker ; BMI great equal 35 Pregnant breastfeed Active duty reserve U.S. military personnel Vaccines Other Injections Any clinically significant AE related vaccination HVTN 205 , revaccination would safety concern grade 3 4 related AE Smallpox vaccine receive within last 5 year HIV vaccine ( ) receive prior HIV vaccine trial HVTN 205 . For HVTN 205 participant subsequently receive control/placebo another HIV vaccine trial , HVTN 114 PSRT determine eligibility casebycase basis . NonHIV experimental vaccine ( ) receive within last 5 year prior vaccine trial . Exceptions may make vaccine subsequently undergone licensure FDA . For volunteer receive control/placebo experimental vaccine trial , HVTN 114 PSRT determine eligibility casebycase basis . For volunteer receive experimental vaccine ( ) great 5 year ago , eligibility enrollment determine HVTN 114 PSRT casebycase basis . Live attenuate vaccine influenza vaccine receive within 30 day first vaccination schedule within 14 day injection ( eg , measles , mumps , rubella [ MMR ] ; oral polio vaccine [ OPV ] ; varicella ; yellow fever ) Influenza vaccine vaccine live attenuate vaccine receive within 14 day prior first vaccination ( eg , tetanus , pneumococcal , Hepatitis A B ) Allergy treatment antigen injection within 30 day first vaccination schedule within 14 day first vaccination Immune System Immunosuppressive medication receive within 168 day first vaccination . ( Not exclusionary : [ 1 ] corticosteroid nasal spray ; [ 2 ] inhaled corticosteroid ; [ 3 ] topical corticosteroid mild , uncomplicated dermatitis ; [ 4 ] single course oral/parenteral corticosteroid dose less 2 mg/kg/day length therapy le 11 day completion least 30 day prior enrollment . ) Serious adverse reaction vaccine vaccine component , include history anaphylaxis relate symptom hive , respiratory difficulty , angioedema , and/or abdominal pain . ( Not exclude participation : volunteer nonanaphylactic adverse reaction pertussis vaccine child . ) Hypersensitivity egg egg product Immunoglobulin receive within 60 day first vaccination Autoimmune disease ( eg , myositis ) Immunodeficiency Cardiac History myocarditis , pericarditis , cardiomyopathy , congestive heart failure permanent sequela , clinically significant arrhythmia ( include arrhythmia require medication , treatment , clinical followup ) ECG clinically significant finding , feature would interfere assessment myo/pericarditis , determine contract ECG Lab cardiologist , include follow : ( 1 ) conduction disturbance ( complete leave complete right bundle branch block nonspecific intraventricular conduction disturbance QRS great equal 120 m , PR interval great equal 220ms , 2nd 3rd degree AV block , QTc prolongation ( great 450ms ) ) ; ( 2 ) repolarization ( ST segment T wave ) abnormality interfere assessment myo/pericarditis ; ( 3 ) significant atrial ventricular arrhythmia ; ( 4 ) frequent atrial ventricular ectopy ( eg , frequent premature atrial contraction , 2 premature ventricular contraction row ) ; ( 5 ) ST elevation consistent ischemia ; ( 6 ) evidence past evolve myocardial infarction Clinically Significant Medical Conditions Untreated incompletely treat syphilis infection Clinically significant medical condition , physical examination finding , clinically significant abnormal laboratory result , past medical history clinically significant implication current health . A clinically significant condition process include limit : A process would affect immune response , A process would require medication affect immune response , Any contraindication repeat injection blood draw , A condition require active medical intervention monitoring avert grave danger volunteer 's health wellbeing study period , A condition process sign symptom could confuse reaction vaccine , Any condition specifically list among exclusion criterion . Any medical , psychiatric , occupational , condition , judgment investigator , would interfere , serve contraindication , protocol adherence , assessment safety reactogenicity , volunteer 's ability give inform consent Psychiatric condition precludes compliance protocol . Specifically excluded person psychosis within past 3 year , ongoing risk suicide , history suicide attempt gesture within past 3 year . Current antituberculosis ( TB ) prophylaxis therapy Asthma mild , wellcontrolled asthma . ( Symptoms asthma severity define recent National Asthma Education Prevention Program ( NAEPP ) Expert Panel report ) . Exclude volunteer : Uses shortacting rescue inhaler ( typically beta 2 agonist ) daily , Uses moderate/high dose inhaled corticosteroid , In past year either follow : Greater 1 exacerbation symptom treat oral/parenteral corticosteroid ; Needed emergency care , urgent care , hospitalization , intubation asthma . Diabetes mellitus type 1 type 2 , include case control diet alone . ( Not exclude : history isolate gestational diabetes . ) Thyroidectomy , thyroid disease require medication last 12 month Hypertension : If person find elevate blood pressure hypertension screen previously , exclude blood pressure well control . Wellcontrolled blood pressure define consistently less equal 140 mm Hg systolic less equal 90 mm Hg diastolic , without medication , isolate , brief instance high reading , must less equal 150 mm Hg systolic less equal 100 mm Hg diastolic . For volunteer , blood pressure must less equal 140 mm Hg systolic less equal 90 mm Hg diastolic enrollment . If person NOT find elevate blood pressure hypertension screen previously , exclude systolic blood pressure great equal 150 mm Hg enrollment diastolic blood pressure great equal 100 mm Hg enrollment . Bleeding disorder diagnose doctor ( eg , factor deficiency , coagulopathy , platelet disorder require special precaution ) Malignancy ( Not exclude participation : Volunteer malignancy excise surgically , investigator 's estimation , reasonable assurance sustain cure , unlikely experience recurrence malignancy period study ) Seizure disorder : History seizure ( ) within past 3 year . Also exclude volunteer use medication order prevent treat seizure ( ) time within past 3 year . Asplenia : condition result absence functional spleen History hereditary angioedema , acquire angioedema , idiopathic angioedema .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>